|
ProBiotix Health PLC on Monday backed its revenue ambitions as it narrowed its loss and posted top line gains. The Wakefield, England-based life sciences business reported a pretax loss of £153,000 for the six months that ended June 30, narrowing from £268,000 a year earlier. Driving the improved earnings was a 34% top-line gain to £1.3 million from £1.0 million, as ProBiotix Health noted that revenue growth exceeded previous years, with it still ‘maintaining gross margin profitability.’ ProBiotix Health said it continued strengthening its position in its core markets across Europe and North America, with it also reporting ‘significant strides’ in the APAC region. It further noted that commercial partnerships in Korea and China are starting to contribute positively, despite their early-stage nature. The firm added that current trading is robust, with its order book at a ‘record level.’ Shares in the company fell 6.8% to 0.069 pence around midday on Monday in London. Looking ahead, ProBiotix Health said it is committed to its ambition of achieving £10 million in revenue by the end of 2028, noting that it is ‘firmly on track’ to deliver on its strategic objectives. ‘We are pleased with the progress that has been achieved in the first half of 2025, which has resulted in another record performance,’ said Chief Executive Steen Andersen. ‘The successful product launches by our partners achieved over the past few years, and the accelerating consumer acceptance, confirms our belief in the tremendous long-term potential for the company. We remain committed to executing the growth strategy to deliver sustainable value for shareholders, and look forward to reporting further on our progress,’ continued Andersen. Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
